The randomized phase III RATIFY trial analyzed the efficacy of Midostaurin in combination with the standard backbone therapy including Cytarabine and Daunorubicin (3 + 7) induction and high dose Cytarabine consolidation in patients <60 years with untreated FLT3 (ITD and/or TKD) AML. The gene discussed is FLT3; the disease is acute myeloid leukemia.